High serum lactate dehydrogenase (LDH) levels are typically associated with a poor
prognosis in many cancer types. Even the most effective drugs, which have radically …

Reprogramming of biochemical pathways is a hallmark of cancer cells, and generation of
lactic acid from glucose/glutamine represents one of the consequences of such metabolic …

Metabolic reprogramming is widely observed during cancer development to confer cancer
cells the ability to survive and proliferate, even under the stressed, such as nutrient-limiting …

Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy
compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is …

Breast cancer is the most common malignancy in women worldwide and is associated with
high mortality rates despite the continuously advancing treatment strategies. Glucose is …

Cancer is a metabolic disease in which abnormally proliferating cancer cells rewire
metabolic pathways in the tumor microenvironment (TME). Molecular reprogramming in the …

Tumor cells possess a high metabolic plasticity, which drives them to switch on the
anaerobic glycolysis and lactate production when challenged by hypoxia. Among the …

Breast cancer is composed of several well-recognized subtypes including estrogen receptor,
progesterone receptor and HER2 triple-negative breast cancer (TNBC). Without available …

Increased glucose consumption distinguishes cancer cells from normal cells and is known
as the" Warburg effect" because of increased glycolysis. Lactate dehydrogenase A (LDHA) …

Abnormal metabolism is a hallmark of cancer, yet its regulation remains poorly understood.
Cancer cells were considered to utilize primarily glycolysis for ATP production, referred to as …